Dawid Walerych

List of Publications by Year
in descending order

20	1,337	759233 12	752698 20
papers	citations	h-index	g-index

21	21	21	2506
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis, 2012, 33, 2007-2017.	2.8	236
2	Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nature Cell Biology, 2016, 18, 897-909.	10.3	205
3	The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities. Biochemical Journal, 2011, 435, 127-142.	3.7	163
4	Hsp90 Regulates the Activity of Wild Type p53 under Physiological and Elevated Temperatures. Journal of Biological Chemistry, 2004, 279, 48846-48854.	3.4	135
5	Hsp90 Chaperones Wild-type p53 Tumor Suppressor Protein. Journal of Biological Chemistry, 2004, 279, 48836-48845.	3.4	134
6	Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. Oncotarget, 2018, 9, 20508-20523.	1.8	86
7	Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions. Oncogene, 2009, 28, 4284-4294.	5.9	75
8	Mutant p53: One, No One, and One Hundred Thousand. Frontiers in Oncology, 2015, 5, 289.	2.8	71
9	Targeting mutant p53 in cancer: a long road to precision therapy. FEBS Journal, 2017, 284, 837-850.	4.7	55
10	Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. Oncogene, 2016, 35, 3760-3770.	5.9	43
11	ATP Binding to Hsp90 Is Sufficient for Effective Chaperoning of p53 Protein. Journal of Biological Chemistry, 2010, 285, 32020-32028.	3.4	34
12	The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Molecular Cancer, 2010, 9, 147.	19.2	26
13	Mutant p53â€“Nrf2 axis regulates the proteasome machinery in cancer. Molecular and Cellular Oncology, 2017, 4, e1217967.	0.7	12
14	Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a â€œdominant-positiveâ€•mechanism. Oncotarget, 2018, 9, 32063-32080.	1.8	12
15	A Driver Never Works Aloneâ€”Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer. Cancers, 2020, 12, 1532.	3.7	12
16	Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency. Frontiers in Molecular Neuroscience, 2021, 14, 676478.	2.9	12
17	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. OncoImmunology, 2017, 6, e1313371.	4.6	11
18	Cooperation of p53 Mutations with Other Oncogenic Alterations in Cancer. Sub-Cellular Biochemistry, 2014, 85, 41-70.	2.4	10

#	Article	IF	Citations
19	Multi-omics reveals global effects of mutant p53 gain-of-function. Cell Cycle, 2016, 15, 3009-3010.	2.6	3
20	Psc3 cohesin of Schizosaccharomyces pombe: cell cycle analysis and identification of three distinct isoforms. Biological Chemistry, 2005, 386, 613-621.	2.5	2